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Abstract  
This study quantifies treatment costs for melanoma and breast, cervical, colorectal, lung, and prostate cancer 
among patients with dual Medicare and Medicaid eligibility. The analyses use merged Medicare and Medicaid 
Analytic eXtract enrollment and claims data for dually eligible beneficiaries age>18 in Georgia, Illinois, 
Louisiana, and Maine in 2003 (n=892,001). We applied ordinary least squares regression analysis to estimate 
annual expenditures attributable to each cancer after controlling for beneficiar ies’ age, race/ethnicity, sex, and 
comorbid conditions, and state fixed effects. Cancers and comorbid conditions were identified on the basis of 
diagnosis codes on insurance claims. The most prevalent cancers were prostate (38.4 per 1,000 men) and breast 
(30.7 per 1,000 women). Dual eligibles with the study cancers had higher rates of other chronic conditions such 
as hypertension and arthritis than other beneficiaries. Total Medicare and Medicaid expenditures for dual 
eligibles with the study cancers ranged from $30,328 for those with lung cancer to $17,011 for those with breast 
cancer, compared with $10,664 for beneficiaries without the cancers. However, only 9% to 30% of medical 
expenditures for dual eligibles with the study cancers were attributable to the cancer itself. In 2003, combined 
Medicare/Medicaid spending for dual eligibles attributable to the six cancers in the four study states exceeded 
$256 million ($314 million in 2012 dollars). Dual eligibles with these cancers also had high rates of other 
medical conditions. These comorbidities should be recognized, both in documenting cancer treatment costs and 
in developing programs and policies that promote timely cancer diagnosis and treatment.  
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Introduction 
Cancer is a leading cause of illness and death 
in the United States. In 2007, more than 1.4 
million new cancer cases were diagnosed and 
almost 560,000 people died from cancer in the 
United States [1]. Annual U.S. expenditures 
for cancer treatment increased from $24.7 
billion in 1987 to an average of $48.1 billion 
during 2001 to 2005 [2]. The burden of cancer 
care falls disproportionately on the Medicare 
program, which provides insurance to 15% of 
the U.S. population [3] but covers 34% of 
cancer treatment costs [2]. 
Although previous studies have estimated the 
cost to Medicare of treating all cancers [2] and 
individual types of cancer [4-7], none have 
looked specifically at cancer treatment costs 
for people with dual eligibility for Medicare 
and Medicaid. Among people with such dual 
eligibility, Medicare is the primary payer for 
acute care services. Depending on a person’s 
income and assets, Medicaid may cover 
Medicare premiums, Medicare deductibles and 
coinsurance, and Medicaid services not 
covered by Medicare, including long-term care 
and, until 2006, outpatient prescription drugs. 
Dually eligible beneficiaries are a 
vulnerable population whose characteristics 
differ from those of other Medicare 
beneficiaries in a number of ways that may 
influence their health care utilization. More 
than 60% have incomes below the federal 
poverty level. In addition, they have a lower 
average education level and are more likely to 
be from a minority population, to live alone, 
and to be institutionalized [8]. Combined 
Medicare and Medicaid spending for dually 
eligible beneficiaries is nearly five times 
higher than Medicare spending for Medicare 
beneficiaries not eligible for Medicaid, and 
Medicare spending alone is nearly twice as 
high [9]. Although dually eligible 
beneficiaries make up only 15% of the 
Medicaid population, they account for 39% of 
Medicaid spending [10]. Dually eligible 
beneficiaries also face the unique challenge of 
having to negotiate both the Medicare system 
and the Medicaid system. The establishment 
on December 30, 2010, of the Federal 
Coordinated Health Care Office, also known 
as the Medicare-Medicaid Coordination Office, 
within the Centers for Medicare & Medicaid 
Services (CMS) reflects heightened attention 
to the needs of dually eligible beneficiaries. 
Although no previous research has been 
conducted concerning cancer treatment costs 
for dually eligible benficiaries, differences 
between dually eligible beneficiaries and other 
Medicare beneficiaries in the type of cancer 
treatment received and the stage of cancer at 
diagnosis have been documented [11-16]. 
These differences are likely to affect cancer 
treatment cost. 
In this study, we used data from four states 
to estimate treatment costs for six types of 
invasive cancers—melanoma and breast, 
cervical, colorectal, lung, and prostate 
cancer—among patients with dual Medicare 
and Medicaid eligibility. We estimated costs 
for each program as well as combined 
Medicare and Medicaid costs. Because the 
prevalence of multiple chronic conditions is 
relatively high among all Medicare 
beneficiaries [17, 18] and especially high 
among those who are dually eligible [17], 
including dually eligible beneficiaries with 
cancer [12], we used multivariate regression 
analysis to estimate costs attributable to each 
of the six types of cancer while controlling for 
comorbid conditions and other beneficiary 
characteristics that may have an impact on 
costs.  
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Materials and methods 
We analyzed merged 2003 Medicare and 
Medicaid Analytic eXtract file (MAX) 
enrollment and claims data for dually eligible 
beneficiaries in four states: Georgia, Illinois, 
Louisiana, and Maine. MAX is a uniform 
dataset containing Medicaid eligibility, 
utilization, and payment information that CMS 
creates from Medicaid Statistical Information 
System (MSIS) data submitted by all U.S. 
states. We analyzed 2003 data because it was 
the most recent year for which MAX data were 
available when our study began. 
We selected the four study states because 
fewer than 10% of their Medicaid beneficiaries 
were enrolled in capitated managed care plans 
in 2003. Although states are required to report 
encounter data for utilization by enrollees in 
capitated managed care plans, CMS does not 
recommend using encounter data for statistical 
analyses because reporting is incomplete and 
the accuracy of the reported encounter data is 
not validated [19]. The states also had 
high-quality cancer registry data, which were 
used in a companion study. 
Because Medicare is the primary payer for 
most services for dually eligible beneficiaries, 
Medicare service coverage does not vary by 
state. However, Medicaid coverage for dually 
eligible beneficiaries in the four study states 
did vary. Illinois and Maine provided full 
Medicaid benefits for dually eligible 
beneficiaries with incomes up to 100% of the 
federal poverty level, whereas Georgia and 
Louisiana provided full benefits only for 
beneficiaries with incomes up to 75%. 
Although there may be state-level differences 
in provision of Medicaid services not covered 
by Medicare, we limited our analyses to 
services that were covered by Medicare and 
excluded the two main categories of Medicaid 
services not covered by Medicare during the 
study period (long-term care and outpatient 
prescription drugs).  
We pooled data from the four states in order to 
have adequate numbers of dually eligible 
beneficiaries with cancer for our analysis. 
Because Medicare covers 91% of inpatient 
expenditures and 88% of ambulatory 
expenditures for dually eligible beneficiaries 
[9], we did not expect differences in state 
Medicaid policies to have an important effect 
on expenditures. Nevertheless, to control for 
variation in Medicaid eligibility and 
reimbursement policies, medical practice 
patterns, and provider supply, we included 
state fixed effects in our regression models. 
The study population consisted of all 
residents of study states aged 18 or older who 
were dually eligible for Medicare and 
Medicaid and had at least 1 month of 
fee-for-service enrollment during 2003. 
Eligibility and utilization data for periods of 
enrollment in capitated managed care were 
excluded from the analyses. We included 
beneficiaries with less than 12 months of 
enrollment because they were a significant 
portion of dually eligible beneficiaries in the 
study states and excluding them could have 
biased our estimates. However, we excluded 
from our analyses eligibility and utilization 
data for these beneficiaries for periods during 
which they were enrolled in capitated managed 
care. 
We calculated mean Medicare and Medicaid 
expenditures in each study state for 
beneficiaries with each of the six study cancers 
(melanoma and breast, cervical, colorectal, 
lung, and prostate cancer) and for all other 
beneficiaries combined, including those with 
nonstudy cancers. We then used multivariate 
regression to estimate marginal expenditures 
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attributable to each study cancer after 
controlling for beneficiaries’ 
sociodemographic characteristics and 
comorbidities. We classified a beneficiary as 
having one the six study cancers if an 
International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9-CM) 
diagnosis code for that type of cancer was in 
any inpatient Medicare or Medicaid claim for 
that beneficiary or in at least two claims on 
different dates for any other type of service for 
that beneficiary. Our prevalence and per capita 
cost estimates for each type of cancer were 
based on data for all dually eligible 
beneficiaries identified as having that type of 
cancer, including those who may no longer be 
receiving active treatment for their cancer.  
We used ordinary least squares multivariate 
regression to estimate per-capita Medicare and 
Medicaid expenditures attributable to each of 
the six study cancers. All analyses were 
conducted with SAS software, version 9.2 
(SAS Institute Inc., Cary, NC). Although 
researchers often use nonlinear two-part 
models to model health care expenditures to 
account for the large percentage of people who 
do not use any services, as well as skewness in 
the distribution of expenditures among service 
users, ordinary least squares has been used in 
some previous analyses of annual medical 
costs [20-22], particularly in analyses that, 
like ours, involved a very large number of 
study subjects.  
We calculated the attributable cost of each 
type of cancer by subtracting predicted 
expenditures for beneficiaries without cancer 
from predicted expenditures for beneficiaries 
with the type of cancer in question while 
holding all other variables in the regressions 
constant at their mean level. Unlike other 
commonly used methods to estimate disease 
costs, the regression approach does not use 
diagnosis or procedure codes to determine 
whether specific claims are for care related to 
the disease in question. The regression 
approach also minimizes the extent to which 
the same medical expenditures are attributed 
to more than one disease by controlling for 
other diseases among people with multiple 
diseases [23, 24].  
The regression models included variables 
indicating whether the individual had each of 
the six study cancers. In addition, the 
regressions controlled for beneficiaries’ age 
(expressed as a continuous variable), age 
squared (to account for non-linear effects of 
age), sex (male, with female omitted), 
race/ethnicity (black, Hispanic, and other, with 
white omitted), the presence of 25 diseases or 
medical conditions (including nonstudy 
cancers), and state fixed effects. We derived 
beneficiaries’ age, sex, and race/ethnicity from 
the Medicare denominator file and used 
procedures similar to those for determining 
their cancer status to determine whether they 
had each of the 25 categories of comorbid 
diseases or conditions (nonmelanoma skin 
cancers, other nonstudied cancers, carcinoma 
in situ, diabetes, hypertension, congestive 
heart failure, stroke, coronary heart disease, 
other cardiovascular diseases, asthma, back 
problems, chronic obstructive pulmonary 
disease, dyslipidemia, HIV/AIDS, injuries, 
pneumonia, pregnancy, renal failure, skin 
problems, arthritis, depression, organic 
psychoses, other mental health or substance 
abuse disorders, mental retardation, and 
degenerative diseases). 
Depending on the regression model, the 
dependent variable was total per-capita 
expenditures for all types of services except 
long-term care and outpatient prescription 
drugs by Medicare, by Medicaid, or by both 
programs combined in 2003. As previously 
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mentioned, we did not include expenditures 
for long-term care and outpatient prescription 
drugs because we were interested in the 
distribution of expenditures for services 
covered by both programs, and Medicare 
provides limited coverage for long-term care 
services and did not begin covering outpatient 
prescription drugs until 2006. Unadjusted 
mean per capita expenditures for long-term 
care services and outpatient prescription drugs 
did not differ significantly between dually 
eligible beneficiaries with and without cancer, 
suggesting that these services are not 
important contributors to cancer-attributable 
costs. 
Results 
The final study population consisted of 
892,001 dually eligible beneficiaries. Table 1 
shows the age, race/ethnicity, sex, and state 
distribution of the study population in the four 
states by whether beneficiaries were diagnosed 
with any of the six study cancers. The 
comparison group includes both individuals 
without cancer and those with nonstudy 
cancers. However, less than 3% of 
beneficiaries in the comparison group had an 
invasive nonstudy cancer (Table 2). 
Beneficiaries with the six study cancers 
accounted for 62% of all beneficiaries with 
cancer in the study population (data not 
shown). Compared with beneficiaries in the 
comparison group, those with study cancers 
were older (mean age 75.1 years vs. 67.8 
years), more likely to be white (67% vs. 64%), 
more likely to be male (38% vs. 34%), and less 
likely to have been enrolled for a full year 
(64% vs. 74%) (Table 1). Nearly half of all 
dually eligible beneficiaries in the study 
resided in Illinois, reflecting the larger size of 
that state’s population compared with the other 
study states.
 Table 1 Distribution of Characteristics Among Dually Eligible Beneficiaries Aged 18 or Older  
 
Beneficiaries with a Study Cancer1 All Others2 All 
Age (mean) 75.1 67.8 *** 68.2 
Race/ethnicity (%) 
  
*** 
 White 67.3 64.2 
 
64.4 
Black 29.6 31.1 
 
31.0 
Hispanic 1.0 1.7 
 
1.6 
Other 2.1 3.1 
 
3.0 
Sex (%) 
  
*** 
 Female 62.2 66.2 
 
66.0 
Male 37.8 33.8 
 
34.0 
State (%) 
  
*** 
 Georgia 26.2 27.8 
 
27.7 
Illinois 50.6 47.7 
 
47.8 
Louisiana 16.8 18.0 
 
18.0 
Maine 6.4 6.5 
 
6.5 
Enrolled for 12 months (%) 64.4 74.4 *** 73.9 
N 48,809  843,192 
 
892,001 
***Significantly different from beneficiaries with a study cancer at p <.001 
1Includes beneficiaries with any of the six study cancers (melanoma or breast, cervical, colorectal, lung, or prostate 
cancer). 
2
Includes beneficiaries with cancers other than the six study cancers.  
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Table 2 Percentage of Dually Eligible Beneficiaries Aged 18 or Older with Selected Comorbid Conditions  
Comorbid Condition  
 
Beneficiaries with a Study Cancer1 
% 
All Others2 
% 
All 
% 
Diabetes 30.5 25.6 *** 25.9 
Hypertension 71.0 57.8 *** 58.5 
Congestive Heart Failure 22.0 13.8 *** 14.2 
Stroke 11.8 8.6 *** 8.8 
Coronary Heart Disease 27.1 16.7 *** 17.3 
Other Cardiovascular Diseases 49.5 30.9 *** 32.0 
Asthma 7.0 5.3 *** 5.4 
Back Problems 15.5 12.0 *** 12.2 
 
Chronic Obstructive Pulmonary Disease 27.9 14.1 *** 14.8 
Depression 11.9 11.5 * 11.5 
Dyslipidemia 20.9 17.4 *** 17.6 
HIV 0.2 0.7 *** 0.7 
Injuries 29.5 20.6 *** 21.1 
Pneumonia 16.0 7.3 *** 7.7 
Pregnancy 0.2 0.4 *** 0.3 
Renal Failure 9.0 6.3 *** 6.5 
Skin Problems 20.1 15.4 *** 15.6 
Arthritis 49.1 37.2 *** 37.9 
 
Mental Health/Substance Abuse 21.0 17.7 *** 17.8 
Organic Psychoses 11.8 8.7 *** 8.9 
Mental Retardation 1.1 3.0 *** 2.9 
Degenerative Diseases 9.1 7.3 *** 7.4 
Cancer In Situ 8.2 0.6 *** 1.1 
Nonmelanoma Skin Cancer 2.3 1.0 *** 1.0 
Other Nonstudy Cancers 11.1 2.6 *** 3.0 
N 48,809 843,192 
 
892,001 
***Significantly different from beneficiaries with a study cancer at p <.001 
*Significantly different from beneficiaries with a study cancer at p <.05 
1 Includes beneficiaries any of the six study cancers (melanoma or breast, cervical, colorectal, lung, or  prostate 
cancer).  2Includes beneficiaries with cancers other than the six study cancers.  
 
Large percentages of dually eligible 
beneficiaries had the comorbid medical 
conditions included in the regression model 
(Table 2). For example, 59% had hypertension, 
38% had arthritis, and 26% had diabetes. With 
the exception of HIV, pregnancy, and mental 
retardation, beneficiaries with one of the six 
study cancers were significantly more likely 
than other beneficiaries to have had each 
condition included in the model. For example, 
  
 
Ivy Union Publishing | http: //www.ivyunion.org April 29, 2013 | Volume 2 | Issue 1  
Haber SG et al. American Journals of Cancer Science 2013, 2:88-100 Page 7 of 13 
they were more than twice as likely to have 
pneumonia, almost twice as likely to have 
chronic obstructive pulmonary disease, and 
about 60% more likely to have congestive 
heart failure, coronary heart disease, and other 
cardiovascular diseases.  
Among all dually eligible beneficiaries, 
prevalence rates (per 1,000 dually eligible 
beneficiaries of both sexes) were 20.2 for 
breast cancer, 13.0 for prostate cancer, 11.6 for 
colorectal cancer, 9.9 for lung cancer, 1.5 for 
cervical cancer, and 1.1 for melanoma (Table 
3). The high overall prevalence of breast 
cancer, however, in part reflects the high 
percentage of women in the study population. 
Prostate cancer rates among men (38.4 per 
1,000) were actually higher than breast cancer 
rates among women (30.7 per 1,000).  
Combined Medicare and Medicaid annual per 
capita expenditures were substantially higher 
for dually eligible beneficiaries with the study 
cancers than for other dually eligible 
beneficiaries (Table 4). Mean combined 
expenditures were $30,328 for those with lung 
cancer, $27,418 for those with cervical cancer, 
$24,885 for those with colorectal cancer, and 
from about $17,000 to $19,000 for those with 
breast cancer, prostate cancer, and melanoma. 
In contrast, the average annual per capita 
expenditure for those who did not have any of 
the study cancers was $10,664. Although 
Medicare covered most expenses for all dually 
eligible beneficiaries, it covered 83-87% of 
costs for those with the study cancers 
compared with only 74% of costs for other 
dually eligible beneficiaries.  
Table 3 Prevalence of Study Cancers per 1,000 Dually Eligible Beneficiaries Aged 18 or Older  
Cancer Type Overall Prevalence Gender-specific Prevalence 
Breast cancer 20.2 30.7 (women only) 
Cervical cancer 1.5 2.3 (women only) 
Colorectal cancer 11.6 N/A 
Lung cancer 9.9 N/A 
Melanoma 1.1 N/A 
Prostate cancer 13.0 38.4 (men only)   
N/A, not applicable (cancer is not gender specific)   
 
Table 4 Mean Annual Per Capita Expenditures for Dually Eligible Beneficiaries Aged 18 or Older 
Cancer Type  
Total Expenditures Medicare Expenditures Medicaid Expenditures 
Mean 
$ 
Standard  
Deviation 
$ 
Mean 
$ 
Standard  
Deviation 
$ 
Percent  
of Total 
Mean 
$ 
Standard  
Deviation 
$ 
Percent 
of Total 
Breast  17,011 22,430 14,144 19,550 83.1 2,867 7,768 16.9 
Cervical 27,418 31,099 23,130 27,789 84.4 4,288 9,466 15.6 
Colorectal 24,885 28,060 21,534 24,760 86.5 3,351 10,230 13.5 
Lung 30,328 28,138 26,430 25,535 87.1 3,897 8,601 12.8 
Melanoma 18,737 22,736 15,528 18,922 82.9 3,208 10,635 17.1 
Prostate 18,131 22,154 15,608 19,947 86.1 2,523 6,779 13.9 
All others1 10,664 21,472 7,900 17,111 74.1 2,764 10,581 25.9 
1 Includes beneficiaries with cancers other than the six study cancers 
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Although dually eligible beneficiaries with 
the study cancers had substantially higher per 
capita expenditures than other dually eligible 
beneficiaries, only a small portion of their 
annual expenditures was attributable to cancer 
(Table 5). Regression-adjusted annual per 
capita expenditures attributable to cancer 
ranged from approximately $9,000 for lung 
cancer to less than $1,700 for melanoma, and 
the share of per capita expenditures 
attributable to cancer ranged from 30% for 
beneficiaries with lung cancer to 9% for those 
with melanoma. The portion of these 
cancer-attributable costs paid by Medicare 
ranged from 89% for breast cancer to 95% for 
melanoma and prostate cancer. Expenditures 
attributable to cancer accounted for a 
substantially larger portion of mean per capita 
Medicare expenditures than mean per capita 
Medicaid expenditures. For example, they 
accounted for 32% of mean Medicare 
expenditures for dually eligible beneficiaries 
with lung cancer but only 13% of mean 
Medicaid expenditures for these beneficiaries.  
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Table 5. Annual Per Capita Expenditures Attributable to Cancer for Dually Eligible Beneficiaries Aged 18 or Older  
 
Total Expenditures Medicare Expenditures Medicaid Expenditures 
Cancer 
Type  
Attributable 
Cost 
$ 
Standard 
Error 
$ 
 
Percentage  
of Mean 
Expenditures 
Attributable 
Cost 
$ 
Standard 
Error 
$ 
 
Percentage  
of Mean 
Expenditures 
Attributable 
Cost 
$ 
Standard 
Error 
$ 
 
Percentage  
of Mean 
Expenditures 
Breast 3,191 128 *** 18.8 2,854 100 *** 20.2 336 74 *** 11.7 
Cervical 6,269 459 *** 22.9 5,838 357 *** 25.2 431 265 
 
10.0 
Colorectal 7,325 168 *** 29.4 6,864 131 *** 31.9 461 97 *** 13.8 
Lung 9,015 185 *** 29.7 8,502 143 *** 32.2 513 107 *** 13.2 
Melanoma 1,641 553 ** 8.8 1,564 430 ** 10.1 77 319 
 
2.4 
Prostate 2,834 161 *** 15.6 2,704 125 *** 17.3 130 93 
 
5.1 
***Significantly different from 0 at p <.001 
**Significantly different from 0 at p <.01 
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Discussion 
In 2003, combined Medicare and Medicaid spending 
for dually eligible beneficiaries in the four study states 
attributable to the six study cancers was about $256 
million, or 23% of total spending for these 
beneficiaries and 3% of spending for all dually eligible 
beneficiaries (excluding expenditures for prescription 
drugs and long-term care). In 2012 dollars, Medicare 
and Medicaid spending for the six cancers was about 
$314 million. Only 9% to 30% of medical 
expenditures for dually eligible beneficiaries with one 
the six types of cancers were attributable to the cancer 
itself. The relatively low proportion of expenditures 
attributable to the study cancers reflects the poor 
health status and high prevalence of comorbidities 
among dually eligible beneficiaries overall and 
especially among those with cancer. Dually eligible 
beneficiaries incurred substantial medical care costs 
for these comorbid conditions independent of their 
cancer status.  
In addition, the study population included 
individuals in varying phases of cancer care, ranging 
from initial treatment to continuing care to terminal 
care. Although we were not able to control for phase 
of care in these claims-based analyses, results from 
previous studies have shown that cancer costs follow a 
U-shaped curve, with the highest costs near diagnosis 
and death [4, 7]. These findings suggest that the share 
of medical expenditures attributable to cancer would 
likely be higher for those patients receiving active 
treatment or end-of-life care.  
Attributable per capita costs were highest for lung 
cancer and colorectal cancer patients, and lowest for 
melanoma and prostate cancer patients. These 
variations in per capita costs may be due to differences 
in factors such as treatment phase-specific costs and 
average duration of patient survival [7]. Study results 
have shown that inpatient services constitute a greater 
proportion of total adjusted long-term costs for colon 
and lung cancer patients than for breast or prostate 
cancer patients [25]. In addition, patients with lung or 
colorectal cancer have been found to survive for a 
shorter time after diagnosis than those with other 
cancers in our study [26]. These findings suggest that 
patients in our study with these two types of cancer 
were more likely to be receiving active treatment or 
end-of-life care, which have been shown to be the two 
most costly phases of cancer care [4, 25, 27]. Results 
from a study of Medicare beneficiaries in the initial 
phase of treatment showed that treatment costs for 
those with lung or colorectal cancer were about twice 
the costs for those with breast or prostate cancer [6]. 
Although these findings were consistent with ours, the 
level of expenditures was much higher, most likely 
because of the relatively high costs during the initial 
phase of treatment. 
Our finding that Medicare covered most costs for 
dually eligible beneficiaries with cancer reflects 
Medicare’s role as the primary payer for most services 
other than long-term care services, for which Medicare 
provides limited coverage, and outpatient prescription 
drugs, which were not covered by Medicare during our 
study period. Although we excluded these services 
from our analyses, they were unlikely to have 
contributed significantly to cancer-attributable costs 
because per capita expenditures for these services 
differed little by beneficiaries’ cancer status.  
This study had four notable limitations. First, 
because our cost estimates were based on data from 
2003, they were less than what Medicare and 
Medicaid costs would be today. Taking into account 
inflation, costs in 2012 would be 25 percent higher 
than our 2003 cost estimates. Although these 
inflation-adjusted expenditure estimates do not 
account for increases in the number of cancer 
treatments or cost increases for cancer treatments that 
differ from general inflation [28], cancer spending as a 
percent of overall medical expenditures and 
expenditures by payer has remained constant over the 
past two decades [2]. This suggests that our estimates 
of the per capita burden of cancer expenditures for 
dually eligible beneficiaries to the Medicare and 
Medicaid programs are not seriously biased by using 
older data. However, our estimate of total expenditures 
attributable to the six cancers does not take into 
account changes since 2003 in the size of the dually 
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eligible population, for example due to economic 
downturn or growth in the population over age 65. 
Second, our estimates of cancer-attributable costs were 
based on expenditures during the calendar year, not 
total treatment costs per diagnosed case. Third, these 
estimates include costs for all cancer patients (both 
incident and prevalent cases) and thus are lower than 
what the average annual cancer-attributable costs 
would have been for a patient in active treatment. We 
were not able to identify treatment phase because 
claims data do not report date of diagnosis. Claims 
data also do not specify cancer stage; thus, we were 
unable to estimate treatment costs by stage of disease. 
Fourth, because our analyses were based on data from 
only four states, our results may not be representative 
of costs for dually eligible beneficiaries in other states.  
Unlike many other cost of illness studies, ours did 
not rely on reporting of specific procedure or diagnosis 
codes to identify cancer treatments. Instead, we used 
regression adjustment to compare all expenditures for 
dually eligible beneficiaries with the six study cancers 
with all expenditures for other dually eligible 
beneficiaries, while controlling for beneficiaries’ 
sociodemographic characteristics and comorbidities. 
We used individual disease indicators, rather than 
other commonly used methods of controlling for 
comorbidities, such as a comorbidity index, because 
our approach more accurately adjusts for an 
individual’s specific disease profile. A single 
comorbidity index variable is useful in analyses based 
on limited data for which a parsimonious model is 
important. However, parsimony was not a significant 
consideration for these analyses because of the large 
number of observations. Although our estimates were 
not affected by inaccuracies in reporting procedure and 
diagnosis codes to identify claims for cancer-related 
expenditures, they may have been affected by 
cancer-related bias in the identification of comorbid 
conditions. Comorbid conditions may be more likely 
to be diagnosed in people with cancer because cancer 
patients see a doctor more often than people without 
cancer. Such bias in the diagnosis of these conditions 
would have led to an underestimate of 
cancer-attributable costs.  
Because of the availability of the Surveillance, 
Epidemiology, and End Results (SEER)-Medicare 
database, many analyses of cancer costs are based 
exclusively on direct Medicare reimbursements and do 
not reflect costs borne by secondary payers or by 
patients. Our findings indicate that the results of such 
analyses understate cancer costs among dually eligible 
beneficiaries by 5-11% depending on the type of 
cancer.  
Although cancer-attributable expenditures for dually 
eligible beneficiaries with any of the six types of 
cancers included in this study were considerable, most 
health care expenditures in this population were not 
attributable to cancer itself but rather to other serious 
medical conditions. Although dually eligible 
beneficiaries in general tend to have a high prevalence 
of these conditions, we found the prevalence rates to 
be even higher among dually eligible beneficiaries 
with cancer, and these other conditions accounted for a 
large proportion of their health care expenditures.  
These findings, which highlight the complexity of 
service needs for dually eligible beneficiaries with 
cancer and the joint role of Medicare and Medicaid in 
covering these services, provide valuable new 
information that can help inform initiatives, such as 
those from the new Federal Coordinated Health Care 
Office, designed to ensure that dually eligible 
beneficiaries have access to seamless, high-quality, 
cost-effective health care. Dually eligible beneficiaries 
often must see multiple providers as a result of their 
substantial health problems, and a cancer diagnosis 
only increases the complexity of their service needs 
and the challenges they face in accessing necessary 
services. These challenges may be a factor in 
previously documented disparities between dually 
eligible beneficiaries and other Medicare beneficiaries 
in the stage of their cancer at diagnosis and in the type 
of cancer treatment they receive [11-14]. The 
challenges in navigating the health care system that are 
encountered by anyone with multiple health problems 
are heightened for dually eligible beneficiaries, who 
are poorer and often less educated than other Medicare 
beneficiaries and who must simultaneously negotiate 
the Medicare and Medicaid programs. The impact of 
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comorbidities on dually eligible beneficiaries with 
cancer should be recognized, not only in documenting 
cancer treatment costs, but also in developing 
programs and policies that promote timely cancer 
diagnosis and treatment. 
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